Your browser doesn't support javascript.
loading
Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.
Wang, Yu; Chen, Xiangyun; Chen, Qiduan; Liu, Tiancai; Wu, Yingsong; Huang, Liping; Chen, Yao.
Afiliação
  • Wang Y; Obstetrics and Gynecology center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Chen X; School of medical laboratory and Biotechnology, Southern Medical University, Guangzhou, China.
  • Chen Q; School of medical laboratory and Biotechnology, Southern Medical University, Guangzhou, China.
  • Liu T; Obstetrics and Gynecology center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Wu Y; School of medical laboratory and Biotechnology, Southern Medical University, Guangzhou, China.
  • Huang L; School of medical laboratory and Biotechnology, Southern Medical University, Guangzhou, China.
  • Chen Y; Obstetrics and Gynecology center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
J Cell Mol Med ; 28(9): e18371, 2024 May.
Article em En | MEDLINE | ID: mdl-38686496
ABSTRACT
Cisplatin (DDP) resistance is a major challenge in treating ovarian cancer patients. A recently discovered enzyme called dCTP pyrophosphatase 1 (DCTPP1) has been implicated in regulating cancer characteristics, including drug responses. In this study, we aimed to understand the role of DCTPP1 in cancer progression and cisplatin response. Using publicly available databases, we analysed the expression and clinical significance of DCTPP1 in ovarian cancer. Our bioinformatics analysis confirmed that DCTPP1 is significantly overexpressed in ovarian cancer and is closely associated with tumour progression and poor prognosis after cisplatin treatment. We also found that DCTPP1 located in oxidoreductase complex and may be involved in various biological processes related to cisplatin resistance, including pyrimidine nucleotide metabolism, the P53 signalling pathway and cell cycle signalling pathways. We observed higher expression of DCTPP1 in cisplatin-resistant cells (SKOV3/DDP) and samples compared to their sensitive counterparts. Additionally, we found that DCTPP1 expression was only enhanced in SKOV3/S cells when treated with cisplatin, indicating different expression patterns of DCTPP1 in cisplatin-sensitive and cisplatin-resistant cancer cells. Our study further supports the notion that cisplatin induces intracellular reactive oxygen species (ROS) and triggers cancer cell death through excessive oxidative stress. Knocking out DCTPP1 reversed the drug resistance of ovarian cancer cells by enhancing the intracellular antioxidant stress response and accumulating ROS. Based on our research findings, we conclude that DCTPP1 has prognostic value for ovarian cancer patients, and targeting DCTPP1 may be clinically significant in overcoming cisplatin resistance in ovarian cancer.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Pirofosfatases / Regulação Neoplásica da Expressão Gênica / Cisplatino / Resistencia a Medicamentos Antineoplásicos Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Pirofosfatases / Regulação Neoplásica da Expressão Gênica / Cisplatino / Resistencia a Medicamentos Antineoplásicos Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article